University of Toronto Schools, Toronto, Ontario, Canada.
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
J Immunol. 2023 Sep 15;211(6):907-916. doi: 10.4049/jimmunol.2300049.
Cancer immunoprevention, the engagement of the immune system to prevent cancer, is largely overshadowed by therapeutic approaches to treating cancer after detection. Vaccines or, alternatively, the utilization of genetically engineered memory T cells could be methods of engaging and creating cancer-specific T cells with superb memory, lenient activation requirements, potent antitumor cytotoxicity, tumor surveillance, and resilience against immunosuppressive factors in the tumor microenvironment. In this review we analyze memory T cell subtypes based on their potential utility in cancer immunoprevention with regard to longevity, localization, activation requirements, and efficacy in fighting cancers. A particular focus is on how both tissue-resident memory T cells and stem memory T cells could be promising subtypes for engaging in immunoprevention.
癌症免疫预防，即利用免疫系统预防癌症，在很大程度上被检测后治疗癌症的治疗方法所掩盖。疫苗或利用基因工程记忆 T 细胞可能是一种方法，可以利用和产生具有出色记忆、宽松激活要求、强大抗肿瘤细胞毒性、肿瘤监测以及对肿瘤微环境中免疫抑制因子的抵抗力的癌症特异性 T 细胞。在这篇综述中，我们根据其在癌症免疫预防中的潜在用途，分析了记忆 T 细胞亚群，涉及寿命、定位、激活要求以及对抗癌症的功效。特别关注的是组织驻留记忆 T 细胞和干细胞记忆 T 细胞如何成为参与免疫预防的有希望的亚型。
